Holen Sie sich die Stockscreener-App
36.99
2.63%
-1.00
Handel nachbörslich:
36.99
Schlusskurs vom Vortag:
$37.99
Offen:
$37.77
24-Stunden-Volumen:
750.91K
Relative Volume:
1.15
Marktkapitalisierung:
$2.20B
Einnahmen:
$45.48M
Nettoeinkommen (Verlust:
$169.95M
KGV:
14.12
EPS:
2.62
Netto-Cashflow:
$230.85M
1W Leistung:
-1.57%
1M Leistung:
+1.04%
6M Leistung:
-4.47%
1J Leistung:
+38.59%
1-Tages-Spanne:
$36.70
$38.01
1-Wochen-Bereich:
$36.70
$39.66
52-Wochen-Spanne:
$24.22
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
36.99 | 2.20B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
665.46 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.02 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.99 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.50 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Average PT from Brokerages - Defense World
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
Protagonist Therapeutics' (PTGX) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Protagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Polycythemia Vera Market Predicted to See Upsurge Through 2034, - openPR
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reiterated at HC Wainwright - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - ETF Daily News
Protagonist Therapeutics’ (PTGX) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $56.00 - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities - Armenian Reporter
Objective long/short (PTGX) Report - Stock Traders Daily
Truist maintains Buy on Protagonist Therapeutics with $60 target - MSN
Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK
Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
JPMorgan Chase & Co. Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price - MarketBeat
Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily
Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex
Protagonist Therapeutics Inc (PTGX) deserves closer scrutiny - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC - Defense World
Top Cancer Experts to Review Game-Changing Blood Disorder TreatmentHere's What's Coming - StockTitan
Protagonist Receives $34 Million from Warrant Exercises - ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
(PTGX) Investment Analysis - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 5.6%Time to Buy? - MarketBeat
Polycythemia Vera Pipeline 2024: Clinical Trials Overview, - openPR
Pacer Advisors Inc. Acquires 142,376 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Inspire Investing LLC - MarketBeat
Protagonist Therapeutics to Participate in Upcoming Investor Conferences - ACCESS Newswire
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress - ACCESS Newswire
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - ACCESS Newswire
Market Recap Check: Protagonist Therapeutics Inc (PTGX)’s Positive Finish at 37.80, Up/Down 2.49 - The Dwinnex
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - ACCESS Newswire
52,239 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Assenagon Asset Management S.A. - MarketBeat
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Protagonist Therapeutics chief medical officer sells shares for tax obligations - Investing.com India
Protagonist Therapeutics chief medical officer sells shares for tax obligations By Investing.com - Investing.com Australia
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $53.78 - Defense World
Protagonist Therapeutics CFO Ali Asif reports stock sale By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 6.2%Time to Sell? - MarketBeat
Long Term Trading Analysis for (PTGX) - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading 8.9% HigherStill a Buy? - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $53.78 Consensus PT from Brokerages - MarketBeat
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck (NASDAQ:PTGX) - Seeking Alpha
Protagonist Therapeutics announces executive role change By Investing.com - Investing.com Australia
Protagonist Therapeutics announces executive role change - Investing.com
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.27%
5.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):